Table 2.

Multivariate analysis evaluating the impact of each HSCT type on acute and chronic GVHD, relapse, NRM, and OS in the older and younger patient cohorts

Acute GVHD24Acute GVHD34Chronic GVHDRelapseNRMOS
Recipient age, ≥50 yHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP value
Donor                   
Younger-H vs CBT 0.52 0.41-0.64 <.001 0.35 0.22-0.57 <.001 1.15 0.93-1.43 .200 1.29 1.07-1.56 .009 0.58 0.45-0.74 <.001 0.83 0.70-0.97 .019 
Older-H vs CBT 0.63 0.42-0.93 .020 0.44 0.20-0.99 .049 0.80 0.50-1.27 .34 1.26 0.88-1.78 .200 0.96 0.65-1.41 .83 1.18 0.90-1.54 .221 
Disease risk                   
High vs low 1.00 0.89-1.14 .950 1.34 1.07-1.66 .009 1.05 0.89-1.24 .540 2.57 2.21-2.99 <.001 1.22 1.06-1.41 .005 2.10 1.89-2.34 <.001 
Disease                   
AML vs others 0.87 0.77-0.99 .030 0.94 0.75-1.17 .590 0.98 0.83-1.15 .780 1.19 1.03-1.38 .020 1.04 0.90-1.20 .6 1.22 1.10-1.36 <.001 
HCT-CI                   
3- vs 1-2 1.17 1.01-1.35 .037 1.13 0.87-1.45 .36 1.03 0.84-1.25 .800 0.93 0.79-1.10 .420 1.48 1.28-1.73 <.001 1.31 1.17-1.47 <.001 
PS24                   
2-4 vs 0,1 0.90 0.70-1.16 .410 1.08 0.72-1.62 .72 0.95 0.68-1.34 .790 1.65 1.34-2.03 <.001 1.31 1.04-1.64 .02 2.00 1.72-2.32 <.001 
RICMAC                   
RIC vs MAC 0.78 0.68-0.88 <.001 0.76 0.60-0.95 .017 0.76 0.64-0.89 <.001 1.21 1.05-1.40 .008 0.77 0.66-0.88 <.001 0.88 0.80-0.99 .032 
Sex mismatch                   
F to M vs others 0.84 0.73-0.97 .015 0.77 0.60-0.99 .042 1.17 0.99-1.40 .073 1.11 0.95-1.29 .190 1.05 0.90-1.21 .56 1.15 1.03-1.28 .013 
Recipient age, <50 y                   
Donor                   
Younger-H vs CBT 0.52 0.37-0.75 <.001 0.18 0.06-0.57 .004 1.01 0.73-1.39 .97 1.30 0.94-1.78 .110 0.70 0.43-1.14 .150 0.91 0.67-1.22 .520 
Older-H vs CBT 1.02 0.78-1.33 .880 1.29 0.80-2.08 .300 1.25 0.93-1.68 .14 0.77 0.50-1.19 .240 0.90 0.58-1.41 .660 0.87 0.63-1.19 .377 
Disease risk                   
High vs low 1.09 0.92-1.29 .290 1.29 0.93-1.78 .130 0.88 0.71-1.09 .24 3.36 2.74-4.13 <.001 1.13 0.88-1.45 .330 2.40 2.03-2.84 <.001 
Disease                   
AML vs others 1.05 0.89-1.23 .570 0.78 0.57-1.07 .120 1.08 0.89-1.30 .45 0.99 0.80-1.21 .900 0.89 0.70-1.14 .360 1.02 0.86-1.21 .818 
HCT-CI                   
3- vs 1-2 0.79 0.61-1.02 .076 0.89 0.55-1.43 .630 1.08 0.82-1.42 .6 0.9 0.66-1.22 .500 1.79 1.33-2.42 <.001 1.35 1.08-1.69 .001 
PS24                   
2-4 vs 0,1 1.14 0.81-1.64 .460 2.10 1.22-3.62 .007 0.99 0.61-1.60 .96 1.57 1.11-2.20 .010 2.12 1.44-3.10 <.001 2.41 1.87-3.11 <.001 
RICMAC                   
RIC vs MAC 0.92 0.73-1.18 .520 0.96 0.61-1.50 .850 1.04 0.80-1.36 .75 1.01 0.75-1.34 .970 0.75 0.52-1.09 .130 0.87 0.68-1.11 .227 
Sex mismatch                   
F to M vs others 0.96 0.80-1.14 .620 0.78 0.54-1.13 .190 1.07 0.86-1.32 .55 0.94 0.74-1.19 .600 1.21 0.92-1.57 .170 1.07 0.89-1.29 .456 
Acute GVHD24Acute GVHD34Chronic GVHDRelapseNRMOS
Recipient age, ≥50 yHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP value
Donor                   
Younger-H vs CBT 0.52 0.41-0.64 <.001 0.35 0.22-0.57 <.001 1.15 0.93-1.43 .200 1.29 1.07-1.56 .009 0.58 0.45-0.74 <.001 0.83 0.70-0.97 .019 
Older-H vs CBT 0.63 0.42-0.93 .020 0.44 0.20-0.99 .049 0.80 0.50-1.27 .34 1.26 0.88-1.78 .200 0.96 0.65-1.41 .83 1.18 0.90-1.54 .221 
Disease risk                   
High vs low 1.00 0.89-1.14 .950 1.34 1.07-1.66 .009 1.05 0.89-1.24 .540 2.57 2.21-2.99 <.001 1.22 1.06-1.41 .005 2.10 1.89-2.34 <.001 
Disease                   
AML vs others 0.87 0.77-0.99 .030 0.94 0.75-1.17 .590 0.98 0.83-1.15 .780 1.19 1.03-1.38 .020 1.04 0.90-1.20 .6 1.22 1.10-1.36 <.001 
HCT-CI                   
3- vs 1-2 1.17 1.01-1.35 .037 1.13 0.87-1.45 .36 1.03 0.84-1.25 .800 0.93 0.79-1.10 .420 1.48 1.28-1.73 <.001 1.31 1.17-1.47 <.001 
PS24                   
2-4 vs 0,1 0.90 0.70-1.16 .410 1.08 0.72-1.62 .72 0.95 0.68-1.34 .790 1.65 1.34-2.03 <.001 1.31 1.04-1.64 .02 2.00 1.72-2.32 <.001 
RICMAC                   
RIC vs MAC 0.78 0.68-0.88 <.001 0.76 0.60-0.95 .017 0.76 0.64-0.89 <.001 1.21 1.05-1.40 .008 0.77 0.66-0.88 <.001 0.88 0.80-0.99 .032 
Sex mismatch                   
F to M vs others 0.84 0.73-0.97 .015 0.77 0.60-0.99 .042 1.17 0.99-1.40 .073 1.11 0.95-1.29 .190 1.05 0.90-1.21 .56 1.15 1.03-1.28 .013 
Recipient age, <50 y                   
Donor                   
Younger-H vs CBT 0.52 0.37-0.75 <.001 0.18 0.06-0.57 .004 1.01 0.73-1.39 .97 1.30 0.94-1.78 .110 0.70 0.43-1.14 .150 0.91 0.67-1.22 .520 
Older-H vs CBT 1.02 0.78-1.33 .880 1.29 0.80-2.08 .300 1.25 0.93-1.68 .14 0.77 0.50-1.19 .240 0.90 0.58-1.41 .660 0.87 0.63-1.19 .377 
Disease risk                   
High vs low 1.09 0.92-1.29 .290 1.29 0.93-1.78 .130 0.88 0.71-1.09 .24 3.36 2.74-4.13 <.001 1.13 0.88-1.45 .330 2.40 2.03-2.84 <.001 
Disease                   
AML vs others 1.05 0.89-1.23 .570 0.78 0.57-1.07 .120 1.08 0.89-1.30 .45 0.99 0.80-1.21 .900 0.89 0.70-1.14 .360 1.02 0.86-1.21 .818 
HCT-CI                   
3- vs 1-2 0.79 0.61-1.02 .076 0.89 0.55-1.43 .630 1.08 0.82-1.42 .6 0.9 0.66-1.22 .500 1.79 1.33-2.42 <.001 1.35 1.08-1.69 .001 
PS24                   
2-4 vs 0,1 1.14 0.81-1.64 .460 2.10 1.22-3.62 .007 0.99 0.61-1.60 .96 1.57 1.11-2.20 .010 2.12 1.44-3.10 <.001 2.41 1.87-3.11 <.001 
RICMAC                   
RIC vs MAC 0.92 0.73-1.18 .520 0.96 0.61-1.50 .850 1.04 0.80-1.36 .75 1.01 0.75-1.34 .970 0.75 0.52-1.09 .130 0.87 0.68-1.11 .227 
Sex mismatch                   
F to M vs others 0.96 0.80-1.14 .620 0.78 0.54-1.13 .190 1.07 0.86-1.32 .55 0.94 0.74-1.19 .600 1.21 0.92-1.57 .170 1.07 0.89-1.29 .456 

CBT, cord blood transplantation; F to M, female to male; GVHD24, grade 2 to 4 GVHD; GVHD34, grade 3 to 4 GVHD; HCT-CI, HCT-specific comorbidity index; Older-H, HSCT from older haplo donor; PS, performance status; Younger-H, HSCT from younger haplo donor.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal